Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma

Journal of Managed Care Pharmacy

Volumn 17, Issue 8, 2011, Pages 610-620

  Hollenbeak, Christopher S ^a   Nikkel, Lucas E ^a   Schaefer, Eric W ^a   Alemao, Evo ^a   Ghahramani, Nasrollah ^a   Raman, Jay D ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; COMORBIDITY; COMPARATIVE STUDY; EMERGENCY CARE; ETHNICITY; FEMALE; HEALTH CARE COST; HOME CARE; HOSPICE CARE; HUMAN; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MEDICARE; OUTPATIENT CARE; RACE;

EID: 83655185984     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.8.610     Document Type: Article

References (38)

1. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol. 2007;25(5):368-75.
2. Hollenbeak CS, Mallick R, Lehman E, Ghahramani N, Reese CT. Treatment and survival among Medicare patients with renal cell carcinoma. Kidney Cancer Journal. 2010;8(2):38-50. Available at: http://www.kidneycancer-journal.com/medicare_v8n2.pdf. Accessed September 3, 2011.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trohi A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
4. Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2008. National Cancer Institute, Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Available at: http://seer.cancer.gov/csr/1975_2008/. Accessed September 3, 2011.
5. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf. Accessed September 3, 2011.
6. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628-31. Available at: http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=10235157. Accessed September 3, 2011.
7. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611-23.
8. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477-90.
9. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193-205.
10. Campbell RJ, Broaddus SB, Leadbetter GW, Jr. Staging of renal cell carcinoma: cost-effectiveness of routine preoperative bone scans. Urology. 1985;25(3):326-29.
11. Fielding JR, Aliabadi N, Renshaw AA, Silverman SG. Staging of 119 patients with renal cell carcinoma: the yield and cost-effectiveness of pelvic CT. AJR Am J Roentgenol. 1999;172(1):23-25. Available at: http://www.ajronline.org/cgi/pmidlookup?view=long&pmid=9888732. Accessed September 3, 2011.
12. Lindner A, Goldman DG, deKernion JB. Cost effective analysis of prenephrectomy radioisotope scans in renal cell carcinoma. Urology. 1983;22(2):127-29.
13. Rámak E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26(24):3995-4000. Available at: http://www.jco.org/cgi/pmidlookup?view=long&pmid=18711190. Accessed September 3, 2011.
14. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95. Available at: http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=16476830. Accessed September 3, 2011.
15. Allareddy V, Konety BR. Inpatient costs for bladder, kidney, and prostate cancers in the year 2002. A study using the NIS sample. Poster presented at: American Urological Association Annual Meeting; May 21, 2006; Atlanta, GA. Available at: http://www.abstracts2view.com/aua_archive/view.php?nu=200691698. Accessed September 3, 2011.
16. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
17. National Cancer Institute. SEER-Medicare: about the data files. October 2010. Available at: http://healthservices.cancer.gov/seermedicare/aboutdata/. Accessed September 3, 2011.
18. National Cancer Institute. SEER-Medicare: number of cases for selected cancers appearing in the data. February 2009. Available at: http://healthservices.cancer.gov/seermedicare/aboutdata/cases.html. Accessed September 3, 2011.
19. Bergstralh E, Kosanke J. GMATCH macro. October 2003. Mayo Foundation for Medical Education and Research. Available at: http://cancercenter.mayo.edu/mayo/research/biostat/sasmacros.cfm/. Accessed September 3, 2011.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
22. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. NIH Pub. No. 01-4969, Bethesda, MD, 2001.
23. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55-61.
24. Hollenbeak CS, Stack BC Jr, Daley SM, Piccirillo JF. Using comorbidity indexes to predict costs for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133(1):24-27. Available at: http://archotol.ama-assn.org/cgi/pmidlookup?view=long&pmid=17224517. Accessed September 3, 2011.
25. Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;169(4):1282-86.
26. Froehner M. Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;170(5):1954.
27. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-96. Available at: http://www.jco.org/cgi/pmidlookup?view=long&pmid=11773181. Accessed September 3, 2011.
28. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-41. Available at: http://www.jco.org/cgi/pmidlookup?view=long&pmid=15681528. Accessed September 3, 2011.
29. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329-43.
30. Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35-47.
31. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505-08.
32. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008;191(4):1220-32. Available at: http://www.ajronline.org/cgi/pmidlookup?view=long&pmid=18806169. Accessed September 3, 2011.
33. Cobb WS, Heniford BT, Matthews BD, Carbonell AM, Kercher KW. Advanced age is not a prohibitive factor in laparoscopic nephrectomy for renal pathology. Am Surg. 2004;70(6):537-42.
34. Pareek G, Yates J, Hedican S, Moon T, Nakada S. Laparoscopic renal surgery in the octogenarian. BJU Int. 2008;101(7):867-70. Available at: http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed& issn=1464-4096&date=2008&volume=101&issue=7&spage=867. Accessed September 3, 2011.
35. Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients-is there a difference? J Urol. 2008;180(4):1262-1266; discussion 1266. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18707708/?tool=pubmed. Accessed September 3, 2011.
36. Saigal CS, Deibert CM, Lai J, Schonlau M. Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma. Urol Oncol. 2010;28(3):308-13. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19070518/?tool=pubmed. Accessed September 3, 2011.
37. Zini L, Perrotte P, Capitanio U, et al. Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU Int. 2009;103(7):889- Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2008.08119.x/full. Accessed September 3, 2011.
38. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179(5):1704-08. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18343443/?tool=pubmed. Accessed September 3, 2011.